Request Demo
Last update 31 May 2025
Anti-CD20/CD22 CAR-T cell therapy (Yake Biotechnology)
Last update 31 May 2025
Overview
Basic Info
Drug Type CAR-T |
Synonyms AntiCD20/22 CART cell therapy Yake Biotechnology, CD20/CD22 dual Targeted CAR Tcell therapy Yake Biotechnology |
Target |
Action inhibitors |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), CD22 inhibitors(CD22 inhibitors), Gene transference(Gene transference) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with Anti-CD20/CD22 CAR-T cell therapy (Yake Biotechnology)ChiCTR1800020021
A single center, single arm, open labelled study for CD20\CD22 Dual Specificity CART Cell Therapy on Relapsed/Refractory B cell Lymphoma or Leukemia
NCT04283006
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies
100 Clinical Results associated with Anti-CD20/CD22 CAR-T cell therapy (Yake Biotechnology)
Login to view more data
100 Translational Medicine associated with Anti-CD20/CD22 CAR-T cell therapy (Yake Biotechnology)
Login to view more data
100 Patents (Medical) associated with Anti-CD20/CD22 CAR-T cell therapy (Yake Biotechnology)
Login to view more data
100 Deals associated with Anti-CD20/CD22 CAR-T cell therapy (Yake Biotechnology)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Adult Lymphoblastic Lymphoma | Phase 1 | China | 23 May 2018 | |
| CD19-positive B-cell acute lymphoblastic leukemia | Phase 1 | China | 23 May 2018 | |
| Chronic Lymphocytic Leukemia | Phase 1 | China | 23 May 2018 | |
| Diffuse Large B-Cell Lymphoma | Phase 1 | China | 23 May 2018 | |
| Diffuse large B-cell lymphoma recurrent | Phase 1 | China | 23 May 2018 | |
| Diffuse large B-cell lymphoma refractory | Phase 1 | China | 23 May 2018 | |
| Follicular Lymphoma | Phase 1 | China | 23 May 2018 | |
| High grade B-cell lymphoma | Phase 1 | China | 23 May 2018 | |
| Philadelphia chromosome positive chronic myelogenous leukemia | Phase 1 | China | 23 May 2018 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free